92 Precision Therapies Are Helping Treat Diseases That Were Previously Undruggable Precision therapies, including RNA-based medicines and “targeted protein degraders” (TPDs), are expanding not only the number of druggable proteins in the human genome, but also the number of treatable tissue types. TPDs Are Expanding The Druggable Proteome Precision Therapies Are Reducing s FDA Approved Druggable Undruggable t The Number Of Duplicative Trials ne100% ge 3 Ge ar S T E e PI ing 80% u A d 44% R o niq2 E C U H - -77% in 60% 79% r T e e t p N o O r s I P 40% ial S r 1 I an T C 56% E m 20% e PR u iv H 17% f 4% icat o l 0% p 0 % Conventional TPD-Enabled u General Precision D The human genome contains ~20,000 protein-coding genes, of which Advanced precision therapy trials are testing a wider variety of biological only 864 (4.3%) are associated with drugs that the FDA has approved. targets than was possible with status quo treatments, lowering the number Human Protein Atlas estimates that 79% (~15,800) of human proteins are of duplicative trials by 77%. As a result, scientists are testing more biological undruggable. Our research indicates that TPDs and adjacent technologies targets per dollar of R&D, increasing the probability of identifying unique could treat 56% (~11,200) of human protein-coding genes. and successful therapies. Data are as of December of 2023 Sources: ARK Investment Management LLC, 2024. This ARK analysis is based on a range of external sources, which may be provided upon request. Forecasts are inherently limited and cannot be relied upon. For informational purposes only and should not be considered investment advice or a recommendation to buy, sell, or hold any particular security. Past performance is not indicative of future results.